Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Weidinger

Showing results (141-150 of 274) with videos related to

Pageof 28
Sort By:
The Journal of Investigative Dermatology|October 22, 2017
Increased Prevalence of Filaggrin Deficiency in 51 Patients with Recessive X-Linked Ichthyosis Presenting for Dermatological ExaminationKira Süßmuth, Robert Gruber, Elke Rodriguez, et al.
The Journal of Allergy and Clinical Immunology|April 9, 2008
Filaggrin mutations, atopic eczema, hay fever, and asthma in childrenStephan Weidinger, Maureen O'Sullivan, Thomas Illig, et al.
The Journal of Investigative Dermatology|April 18, 2014
An integrated epigenetic and transcriptomic analysis reveals distinct tissue-specific patterns of DNA methylation associated with atopic dermatitisElke Rodríguez, Hansjörg Baurecht, Anna Franziska Wahn, et al.
Journal of the American Academy of Dermatology|December 29, 2024
The efficacy of longer-term lebrikizumab treatment in patients with moderate-to-severe atopic dermatitis who did not meet protocol-defined response criteria at week 16 in 2 randomized controlled clinical trialsEmma Guttman-Yassky, David Rosmarin, Marjolein de Bruin-Weller, et al.
The British Journal of Dermatology|September 23, 2025
Efficacy and safety of lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis inadequately controlled with or ineligible for ciclosporin A: a placebo-controlled, randomized phase IIIb clinical study (ADvantage)Richard B Warren, Marjolein de Bruin-Weller, Athanasios Tsianakas, et al.
The Journal of Allergy and Clinical Immunology|July 2, 2005
Association of NOD1 polymorphisms with atopic eczema and related phenotypesStephan Weidinger, Norman Klopp, Lars Rummler, et al.
Acta Dermato-Venereologica|January 25, 2021
Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic TherapiesMarjolein De Bruin-Weller, Tilo Biedermann, Robert Bissonnette, et al.
The Journal of Allergy and Clinical Immunology|January 4, 2021
Elevated NK-cell transcriptional signature and dysbalance of resting and activated NK cells in atopic dermatitisLena Möbus, Elke Rodriguez, Inken Harder, et al.
Human Genomics|November 27, 2022
The integration of large-scale public data and network analysis uncovers molecular characteristics of psoriasisAntonio Federico, Alisa Pavel, Lena Möbus, et al.
JCI Insight|July 13, 2018
Meta-analysis of RNA sequencing datasets reveals an association between TRAJ23, psoriasis, and IL-17AAlexander A Merleev, Alina I Marusina, Chelsea Ma, et al.
Pageof 28

Showing results (141-150 of 274) with videos related to

Sort By:
Pageof 28
The Journal of Investigative Dermatology|October 22, 2017
Increased Prevalence of Filaggrin Deficiency in 51 Patients with Recessive X-Linked Ichthyosis Presenting for Dermatological ExaminationKira Süßmuth, Robert Gruber, Elke Rodriguez, et al.
The Journal of Allergy and Clinical Immunology|April 9, 2008
Filaggrin mutations, atopic eczema, hay fever, and asthma in childrenStephan Weidinger, Maureen O'Sullivan, Thomas Illig, et al.
The Journal of Investigative Dermatology|April 18, 2014
An integrated epigenetic and transcriptomic analysis reveals distinct tissue-specific patterns of DNA methylation associated with atopic dermatitisElke Rodríguez, Hansjörg Baurecht, Anna Franziska Wahn, et al.
Journal of the American Academy of Dermatology|December 29, 2024
The efficacy of longer-term lebrikizumab treatment in patients with moderate-to-severe atopic dermatitis who did not meet protocol-defined response criteria at week 16 in 2 randomized controlled clinical trialsEmma Guttman-Yassky, David Rosmarin, Marjolein de Bruin-Weller, et al.
The British Journal of Dermatology|September 23, 2025
Efficacy and safety of lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis inadequately controlled with or ineligible for ciclosporin A: a placebo-controlled, randomized phase IIIb clinical study (ADvantage)Richard B Warren, Marjolein de Bruin-Weller, Athanasios Tsianakas, et al.
The Journal of Allergy and Clinical Immunology|July 2, 2005
Association of NOD1 polymorphisms with atopic eczema and related phenotypesStephan Weidinger, Norman Klopp, Lars Rummler, et al.
Acta Dermato-Venereologica|January 25, 2021
Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic TherapiesMarjolein De Bruin-Weller, Tilo Biedermann, Robert Bissonnette, et al.
The Journal of Allergy and Clinical Immunology|January 4, 2021
Elevated NK-cell transcriptional signature and dysbalance of resting and activated NK cells in atopic dermatitisLena Möbus, Elke Rodriguez, Inken Harder, et al.
Human Genomics|November 27, 2022
The integration of large-scale public data and network analysis uncovers molecular characteristics of psoriasisAntonio Federico, Alisa Pavel, Lena Möbus, et al.
JCI Insight|July 13, 2018
Meta-analysis of RNA sequencing datasets reveals an association between TRAJ23, psoriasis, and IL-17AAlexander A Merleev, Alina I Marusina, Chelsea Ma, et al.
Pageof 28